HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hawaii Puts Hold On Proposal To Blacklist Additional Sunscreen Ingredients

Executive Summary

Proposed bills in the Aloha State would ban the sale of sunscreens containing octocrylene and/or avobenzone, adding to a UV filter blacklist that already includes oxybenzone and octinoxate. On 17 February, Hawaiian legislators elected to defer the legislation to await completion of a National Academy of Sciences study, targeted for 2022.

You may also be interested in...



Sun Setting On Attempts To Expand Hawaii Sunscreen Ingredient Ban During 2021

Advocates hoped a study suggesting octocrylene in sunscreens may degrade into benzophenone would convince lawmakers to expand ban, but a House committee maintained its commitment to wait on more research.

OTC Sunscreen Ingredients’ Environmental Impacts Likely To Be Growing Discussion, Including At US FDA

Designating new “critical habitats” off US shores, as proposed by the National Marine Fisheries Service, would require federal agencies “to ensure that actions they plan to undertake, fund, or authorize do not destroy or adversely modify that habitat.” That could factor in the US FDA’s OTC sunscreen review program and potential follow-up on a 2018 citizen petition calling for a ban on "coral-killing" UV filters.

CARES Act Makes Threatened Sunscreen Ingredients GRASE Again, But Next Steps Uncertain

Many questions remain following the late March enactment of the US CARES Act, which overhauls the FDA’s OTC drug regulatory framework and resets the GRASE status of long-used sunscreen drug ingredients whose safety and effectiveness have come under question at the FDA.

Related Content

Topics

UsernamePublicRestriction

Register

RS151031

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel